Vascular Access Device Market OverviewThe global vascular access device market is witnessing consistent growth and is ...
A Chesterfield medical device company has earned an FDA breakthrough designation for its vein dilation system designed to help dialysis patients. The designation could significantly speed up the ...
DaVita (NYSE:DVA) executives told investors the company closed 2025 with fourth-quarter results “in line with our ...
Phraxis Inc. today announced the successful initiation of its Post-Approval Study (PAS) for the EndoForce™ Anastomotic ...
DaVita Inc. (NYSE:DVA) Q4 2025 Earnings Call Transcript February 2, 2026 DaVita Inc. beats earnings expectations. Reported ...
Graft stenosis, which can lead to thrombosis, is a major problem in hemodialysis patients with arteriovenous grafts. Does anti-aggregation with dipyridamole and aspirin help to prolong the primary ...
South Africa faces a critical kidney transplant shortage, with rising kidney failure cases, limited dialysis access and low ...
Nephrology care in the United States plays a critical role in managing chronic kidney disease, end-stage renal disease, and dialysis-dependent patients. As treatment demands increase, nephrology pract ...
Fresenius Medical Care faces ongoing market disinterest, as years of decent free cash flow generation have failed to drive meaningful market returns. Elevated U.S. mortality, a rough flu season, China ...
Compass Surgical Partners and local physicians have opened the Cardiovascular Surgical Institute of Northwest Florida in ...
Asianet Newsable on MSN
Why did DaVita stock jump 15% after hours today?
DaVita said its integrated kidney care unit hit full-year profitability in 2025, a year ahead of its original 2026 target.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results